Document:

Filed by sedaredgar.com - Liberty Energy Corp. - Exhibit 10.2

CONSULTING AGREEMENT 

THIS AGREEMENT is made effective this
1st day of February, 2010. 

BETWEEN: 

LIBERTY ENERGY CORP., a body
corporate duly incorporated under the laws of the State of Nevada, and having an
office at Two Allen Center, Suite 1600, 1200 Smith Street, Houston, TX 77002

(hereinafter called the "Company")

OF THE FIRST PART 

AND: 

IAN SPOWART having an office at
34 Hampton Road, Town Moor, Doncaster, UK, DN2 5DG 

(hereinafter called the "Consultant")

OF THE SECOND PART 

WHEREAS: 

A.                    
The Consultant has been appointed CEO of the Company by the board of Directors;

B.                    
The Company is desirous of retaining the consulting services of the Consultant
on a continuing basis and the Consultant has agreed to serve the Company as an
independent contractor upon the terms and conditions hereinafter set forth; 

FOR VALUABLE CONSIDERATION it is hereby agreed as follows: 

1.                    
  The Consultant shall provide services customary to the position of a CEO of
  a publicly listed company in the United States. Without limiting the preceding,
  such services will typically consist of: corporate administration and mineral
  exploration consulting services to the Company, mineral industry consulting
  services, strategic corporate and financial planning, management of the overall
  business operations of the Company, and supervising exploration activities,
  office staff and other consultants, and the Consultant shall serve the Company
  (and/or such subsidiary or subsidiaries of the company as the Company may from
  time to time require) in such consulting capacity or capacities as may from
  time to time be determined by resolution of the Board of Directors of the Company
  and shall perform such duties and exercise such powers as may from time be determined
  by resolution of the Board of Directors, as an independent contractor. 

- 2 - 

2.                    
The basic remuneration of the Consultant for its services hereunder shall be at
the rate of six thousand five hundred United States dollars (US$6,500) per
month, together with any such increments thereto as the Board of Directors of
the Company determine after six months, payable on the last business day of each
calendar month. The basic compensation covers one hundred twenty (120) working
hours per month of Consultant’s time.

3.                    
The Consultant agrees to comply with all applicable securities legislation and
regulatory policies in relation to providing the Services, including but not
limited to United States securities laws (in particular, Regulation FD) and the
policies of the United States Securities and Exchange Commission. 

4.                   
 The Consultant hereby acknowledges that the Consultant is aware, and
further agrees that the Consultant will advise those of its directors, officers,
employees and agents who may have access to Confidential Information, that
United States securities laws prohibit any person who has material, non-public
information about a company from purchasing or selling securities of such a
company or from communicating such information to any other person under
circumstances in which it is reasonably foreseeable that such person is likely
to purchase or sell such securities.

5.                   
 The Consultant shall be responsible for the payment of its income tax
remittances as shall be required by any governmental entity with respect to
compensation paid by the Company to the Consultant. 

6.                    
  The terms "subsidiary" and "subsidiaries" as used herein mean any corporation
  or company of which more than 50% of the outstanding shares carrying voting
  rights at all times (provided that the ownership of such shares confers the
  right at all times to elect at least a majority of the Board of Directors of
  such corporation or company) are for the time being owned by or held for the
  Company and/or any other corporation or company in like relation to the Company
  and include any corporation or company in like relation to a subsidiary. 

- 3 - 

7.                    
  The Consultant shall be reimbursed for all travelling and other expenses actually
  and properly incurred by it in connection with its duties hereunder. For all
  such expenses the Consultant shall furnish to the Company statements, receipts
  and vouchers for such out-of-pocket expenses on a monthly basis. 

8.                    
The Consultant shall not, either during the continuance of its contract
hereunder or at any time thereafter, disclose the private affairs of the Company
and/or its subsidiary or subsidiaries, or any secrets of the Company and/or its
subsidiary or subsidiaries, to any person other than the Directors of the
Company and/or its subsidiary or subsidiaries or for the Company's purposes and
shall not (either during the continuance of its contract hereunder or at any
time thereafter) use for its own purposes or for any purpose other than those of
the Company any information it may acquire in relation to the business and
affairs of the Company and/or its subsidiary or subsidiaries. 

9.                    
The Consultant shall well and faithfully serve the Company or any subsidiary as
aforesaid during the continuance of its contract hereunder and use its best
efforts to promote the interests of the Company. 

10.                  
Without prejudicing any other rights that the Company may have hereunder or at
law or in equity, the Company may terminate this Agreement immediately upon
delivery of written notice to the Consultant if: 

	 	a) 	
      the Consultant breaches this Agreement;

	 	 	 
	 	b) 	
      the Consultant breaches any other material term of this
      Agreement and such breach is not cured to the reasonable satisfaction of
      the Company within thirty (30) days after written notice describing the
      breach in reasonable detail is delivered to the Consultant;

	 	 	 
	 	c) 	
      the Company acting reasonably determines that the
      Consultant has acted, is acting or is likely to act in a manner
      detrimental to the Company or has violated or is likely to violate the
      confidentiality of any information as provided for in this
    Agreement;

	 	 	 
	 	d) 	
      the Consultant is unable or unwilling to perform the
      Services under this Agreement, or

	 	 	 
	 	e) 	
      the Consultant commits fraud, serious neglect or
      misconduct in the discharge of the Services.

	 	 	 
	 	f) 	 The Consultant shall be convicted of any criminal offence
        other than an offence which, in the reasonable opinion of the Board of
        Directors of the Company, does not affect their position as a Consultant
        or a director of the Company. 

- 4 - 

                        
This Agreement may also be terminated by either party upon thirty (30) days
written notice to the other. 

11.                  
Upon termination of this Agreement for any reason, the Consultant shall upon
receipt of all sums due and owing, promptly deliver the following in accordance
with the directions of the Company: 

	 	a) 	
      a final accounting, reflecting the balance of expenses
      incurred on behalf of the Company as of the date of termination;
  and

	 	 	 
	 	b) 	
      all documents pertaining to the Company or this
      Agreement, including but not limited to, all books of account,
      correspondence and contracts, provided that the Consultant shall be
      entitled thereafter to inspect, examine and copy all of the documents
      which it delivers in accordance with this provision at all reasonable
      times upon three (3) days’ notice to the Company.

12.                  
In the event this Agreement is terminated by reason of default on the part of
the Consultant or the written notice of the Company, then at the request of the
Board of Directors of the Company, the Consultant shall forthwith resign any
position or office which he then holds with the Company or any subsidiary of the
Company. The provisions of paragraph 9 shall survive the termination of this
Agreement. 

13.                  
  The Consultant acknowledges that in the course of its appointment hereunder
  the Consultant will, either directly or indirectly, have access to and be entrusted
  with information (whether oral, written or by inspection) relating to the Company
  or its respective affiliates, associates or customers (the “Confidential
  Information”). For the purposes of this Agreement, “Confidential
  Information” includes, without limitation, any and all Developments (as
  defined herein), trade secrets, inventions, innovations, techniques, processes,
  formulas, drawings, designs, products, systems, creations, improvements, documentation,
  data, specifications, technical reports, customer lists, supplier lists, distributor
  lists, distribution channels and methods, retailer lists, reseller lists, employee
  information, financial information, sales or marketing plans, competitive analysis
  reports and any other thing or information whatsoever, whether copyrightable
  or uncopyrightable or patentable or unpatentable. 

- 5 - 

The Consultant acknowledges that the Confidential Information
  constitutes a proprietary right, which the Company is entitled to protect. Accordingly
  the Consultant covenants and agrees that during the Term and thereafter until
  such time as all the Confidential Information becomes publicly known and made
  generally available through no action or inaction of the Consultant, the Consultant
  will keep in strict confidence the Confidential Information and shall not, without
  prior written consent of the Company in each instance, disclose, use or otherwise
  disseminate the Confidential Information, directly or indirectly, to any third
  party. 

14.                  
The general prohibition contained in Section 13 against the unauthorized
disclosure, use or dissemination of the Confidential Information shall not apply
in respect of any Confidential Information that: 

	 	a) 	
      is available to the public generally in the form
      disclosed;

	 	 	 
	 	b) 	
      becomes part of the public domain through no fault of the
      Consultant;

	 	 	 
	 	c) 	
      is already in the lawful possession of the Consultant at
      the time of receipt of the Confidential Information; or

	 	 	 
	 	d) 	
      is compelled by applicable law to be disclosed, provided
      that the Consultant gives the Company prompt written notice of such
      requirement prior to such disclosure and provides assistance in obtaining
      an order protecting the Confidential Information from public
      disclosure.

15.                  
  Any information, data, work product or any other thing or documentation whatsoever
  which the Consultant, either by itself or in conjunction with any third party,
  conceives, makes, develops, acquires or acquires knowledge of during the Consultant’s
  appointment with the Company or which the Consultant, either by itself or in
  conjunction with any third party, shall conceive, make, develop, acquire or
  acquire knowledge of (collectively the “Developments”) during
  the Term or at any time thereafter during which the Consultant is engaged by
  the Company that is related to the business of the Company shall automatically
  form part of the Confidential Information and shall become and remain the sole
  and exclusive property of the Company. Accordingly, the Consultant does hereby
  irrevocably, exclusively and absolutely assign, transfer and convey to the Company
  in perpetuity all worldwide right, title and interest in and to any and all
  Developments and other rights of whatsoever nature and kind in or arising from
  or pertaining to all such Developments created or produced by the Consultant
  during the course of performing this Agreement, including, without limitation,
  the right to effect any registration in the world to protect the foregoing rights.
  The Company shall have the sole, absolute and unlimited right throughout the
  world, therefore, to protect the Developments by patent, copyright, industrial
  design, trademark or otherwise and to make, have made, use, reconstruct, repair,
  modify, reproduce, publish, distribute and sell the Developments, in whole or
  in part, or combine the Developments with any other matter, or not use the Developments
  at all, as the Company sees fit. 

- 6 - 

16.                  
The Consultant does hereby agree that, both before and after the termination of
this Agreement, the Consultant shall perform such further acts and execute and
deliver such further instruments, writings, documents and assurances (including,
without limitation, specific assignments and other documentation which may be
required anywhere in the world to register evidence of ownership of the rights
assigned pursuant hereto) as the Company shall reasonably require in order to
give full effect to the true intent and purpose of the assignment made under
Section 15 hereof. If the Company is for any reason unable, after reasonable
effort, to secure execution by the Consultant on documents needed to effect any
registration or to apply for or prosecute any right or protection relating to
the Developments, the Consultant hereby designates and appoints the Company and
its duly authorized officers and agents as the Consultant’s agent and attorney
to act for and in the Consultant’s behalf and stead to execute and file any such
document and do all other lawfully permitted acts necessary or advisable in the
opinion of the Company to effect such registration or to apply for or prosecute
such right or protection, with the same legal force and effect as if executed by
the Consultant. 

17.                  
The parties to this Agreement recognize that any violation or threatened
violation by the Consultant of any of the provisions contained in this Agreement
will result in immediate and irreparable damage to the Company and that the
Company could not adequately be compensated for such damage by monetary award
alone. Accordingly, the Consultant agrees that in the event of any such
violation or threatened violation, the Company shall, in addition to any other
remedies available to the Company at law or in equity, be entitled as a matter
of right to apply to such relief by way of restraining order, temporary or
permanent injunction and to such other relief as any court of competent
jurisdiction may deem just and proper. 

20.                  
The Consultant agrees that all restrictions in this Agreement are reasonable and
valid, and all defenses to the strict enforcement thereof by the Company are
hereby waived by the Consultant. 

- 7 - 

21.                  
The Company is aware that the Consultant has now and will continue to have
financial interests in other companies and properties and the Company recognizes
that these companies and properties will require a certain portion of the
Consultant's time. The Company agrees that the Consultant may continue to devote
time to such outside interests, PROVIDED THAT such interests do not conflict
with, in any way, the time required for the Consultant to perform its duties
under this Agreement. 

22.                  
The services to be performed by the Consultant pursuant hereto are personal in
character, and neither this Agreement nor any rights or benefits arising
thereunder are assignable by the Consultant without the previous written consent
of the Company. 

23.                  
Any and all previous agreements, written or oral, between the parties hereto or
on their behalf relating to the agreement between the Consultant and the Company
are hereby terminated and cancelled and each of the parties hereto hereby
releases and forever discharges the other party hereto of and from all manner of
actions, causes of action, claims and demands whatsoever under or in respect of
any such previous agreements. 

24.                  
Any notice in writing or permitted to be given to the Consultant hereunder shall
be sufficiently given if delivered to the Consultant personally or mailed by
registered mail, postage prepaid, addressed to the Consultant as its last
residential address known to the Company. Any such notice mailed as aforesaid
shall be deemed to have been received by the Consultant on the first business
day following the date of mailing. Any notice in writing required or permitted
to be given to the Company hereunder shall be given by registered mail, postage
prepaid, addressed to the Company at the address shown on page 1 hereof. Any
such notice mailed as aforesaid shall be deemed to have been received by the
Company on the first business day following the date of mailing. Any such
address for the giving of notices hereunder may be changed by notice in writing
given hereunder. 

25.                  
The provisions of this Agreement shall enure to the benefit of and be binding
upon the Consultant and the successors and assigns of the Company. For this
purpose, the terms "successors" and "assigns" shall include any person, firm or
corporation or other entity which at any time, whether by merger, purchase or
otherwise, shall acquire all or substantially all of the assets or business of
the Company. 

- 8 - 

26.                  
Every provision of this Agreement is intended to be severable. If any term or
provision hereof is illegal or invalid for any reason whatsoever, such
illegality or invalidity shall not affect the validity of the remainder of the
provisions of this Agreement. 

27.                  
This Agreement is being delivered and is intended to be performed in the
Province of British Columbia and shall be construed and enforced in accordance
with, and the rights of the parties shall be governed by, the laws of such
Province. This Agreement may not be changed orally, but only by an instrument in
writing signed by the party against whom or which enforcement of any waiver,
change, modification or discharge is sought. 

28.                  
This Agreement and the obligations of the Company herein are subject to all
applicable laws and regulations in force at the local, State, Province, and
Federal levels.

                        
IN WITNESS WHEREOF this Agreement has been executed as of the day, month and
year first above written. 

Signed this 11th day of February, 2010 

LIBERTY ENERGY CORP.

 

/s/ Daniel
Martinez-Atkinson                                   
Per:
Daniel Martinez-Atkinson, CFO 

 

IAN SPOWART 

 

/s/ Ian
SpowartFiled by sedaredgar.com - Caleco Pharma Corp - Exhibit 10.3

SHARE PURCHASE AGREEMENT

THIS AGREEMENT is dated for reference as of the 10th day
  of February, 2010.

	AMONG: 	
	 	  
	 	NATAC BIOTECH S.L., a Spanish
      corporation having an address at 
	 	Calle Ana de Austria 7, 28660 Bodilla del
      Monte, Madrid, Spain. 
	 	  
	 	(hereinafter called "Natac") 
	 	           
                         
                         
                         
                         
                         
                         
                         
                         
                         
                   OF THE FIRST PART
    
	 	  
	 AND: 	
	 	  
	 	ANTONIO DELGADO ROMERO, an
      individual having an address at 
	 	Calle Manuel de Falla 4a, 05260 Avila, Spain.
    
	 	  
	 	(hereinafter called "Romero") 
	 	           
                         
                         
                         
                         
                         
                         
                         
                         
                         
         OF THE SECOND PART 
	 AND:	 
	 	  
	 	JOSE CARLOS QUINTELA FERNANDEZ,
      an individual having an 
	 	address at Calle Tellez 25, 2do, Puerta 1,
      28007, Madrid, Spain. 
	 	  
	 	(hereinafter called "Fernandez") 
	 	           
                         
                         
                         
                         
                         
                         
                         
                         
                         
                 OF THE THIRD PART 
	 	  
	 AND: 	
	 	  
	 	CALECO PHARMA CORP., a Nevada
      corporation having an 
	 	address at Suite 410 – 103 East Holly Street,
      National Bank Building, 
	 	Bellingham, WA 98225. 
	 	  
	 	(hereinafter called "Caleco") 
	 	           
                         
                         
                         
                         
                         
                         
                         
                         
                         
           OF THE FOURTH PART 

WHEREAS:

A.          
   Romero and Fernandez (the “Vendors”) each own 98 shares
  of the capital stock of Natac;

B.           
  Caleco has offered to purchase 18 shares of Natac from Romero and 18
  shares of Natac from Fernandez, representing an aggregate of 36 shares of Natac
  (the “Natac Shares”); and

C.           
  The Vendors have agreed to transfer the Natac Shares to Caleco on the
  terms and conditions set forth herein.

NOW THEREFORE THIS AGREEMENT WITNESSES that in
consideration of the foregoing and of the sum of $10.00 paid by Caleco to Natac
and the Vendors, the receipt of which is hereby acknowledged, the parties hereto
agree each with the other as follows:

	1. 	
      INTERPRETATION

	 	 	 
	1.1 	
      Where used herein, the following terms shall have the
      following meanings:

	 	 	 
		(a) 	
      "Caleco Shares" means 4,300,000 shares of common stock of
      Caleco.

	 	 	 
		(b) 	
      "Closing Date" has the meaning set forth in Section 7.1
      of this Agreement.

	 	 	 
		(c) 	
      "Exchange Act" means the United States Securities
      Exchange Act of 1934, as amended.

	 	 	 
		(d) 	
      "Natac Shares" means 36 shares of the capital stock of
      Natac, consisting of 18 shares of Natac owned by Romero and numbered 1 to
      18, inclusive; and 18 shares of Natac owned by Fernandez and numbered 99
      to 116 inclusive.

	 	 	 
		(e) 	
      "SEC" means the Securities and Exchange
  Commission.

	 	 	 
		(f) 	
      "Securities Act" means the United States Securities Act
      of 1933, as amended.

	 	 	 
		(g) 	
      "Vendors" means, collectively, Romero and Fernandez, and
      “Vendor” means any one of the Vendors.

	 	 	 
	2. 	
      SHARE PURCHASE

2.1           
  Upon the terms and subject to the conditions of this Agreement, the
  Vendors hereby agree to sell to Caleco, and Caleco hereby agrees to purchase
  from the Vendors, the following shares of Natac (collectively, the “Natac
  Shares”), free and clear of all liens, charges and encumbrances whatsoever:

	 	Antonio Delgado Romero 	18 shares in the capital stock of Natac 
	 	Jose Carlos Quintela Fernandez 	18 shares in the capital stock of Natac
  

2.2           
  In consideration for the sale of the Natac Shares by the Vendors to
  Caleco, Caleco shall issue to the Vendors the following shares of Caleco (collectively,
  the “Caleco Shares”), free and clear of all liens, charges and encumbrances
  whatsoever:

	 	Antonio Delgado Romero 	2,150,000 shares of common stock of Caleco
  
	 	Jose Carlos Quintela Fernandez 	2,150,000 shares of common stock of Caleco
  

2.3           
  Each Vendor acknowledges that the Caleco Shares are “restricted
  securities” within the meaning of the Securities Act and will be issued
  to each Vendor in accordance with Regulation S of the Securities Act. Any certificates
  representing the Caleco Shares will be endorsed with the following legend in
  accordance with Regulation S of the Securities Act:

“THE SECURITIES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE
“ACT”), AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION
REQUIREMENTS OF THE ACT PROVIDED BY REGULATION S PROMULGATED UNDER THE ACT. SUCH
SECURITIES MAY NOT BE REOFFERED FOR SALE OR RESOLD OR
OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S,
PURUSANT TO AN EFFECTIVE REGISTRATION UNDER THE ACT, OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM REGISTRATION UNDER THE ACT. HEDGING TRANSACTIONS INVOLVING THE
SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT.”

3.           
COVENANTS OF NATAC AND CALECO

3.1          
If Natac offers to issue additional shares and Natac’s outstanding
share capital is 4,000,000 Euros or less and Caleco’s market capitalization is
equal to or greater than $21,000,000, Natac shall issue to Caleco, for no
additional consideration, the same class of shares to Caleco and such number of
shares equal to eighteen percent (18%) of the issued shares following their
issuance.

3.2          
If Natac offers to issue additional shares and Natac’s share capital is
above 4,000,000 Euros at the time of the issuance or Caleco’s market
capitalization is less than $21,000,000, Natac shall grant Caleco a right to
purchase, for the same price and on the same terms, the same class of shares
offered and such number of shares equal to eighteen percent (18%) of the issued
shares following their issuance.

3.3          
Upon closing and for so long as Caleco holds the Natac Shares, Caleco
shall be entitled to appoint one of its representatives to the Board of
Directors of Natac.

3.4          
Upon closing, Natac shall be entitled to appoint one of its
representatives to the Board of Directors of Caleco.

4.          
 REPRESENTATIONS AND WARRANTIES OF NATAC AND THE
VENDORS

              
Natac and the Vendors jointly and severally represent and warrant to
Caleco as follows, and acknowledge that Caleco is relying upon such
representations and warranties in connection with the acquisition of the Natac
Shares by Caleco:

4.1          
Natac has been duly incorporated and organized and is validly
subsisting under the laws of Spain; it has the corporate power to own or lease
its properties and to carry on its business as now being conducted by it; and it
is duly qualified as a corporation to do business and is in good standing with
respect thereto in each jurisdiction in which the nature of its business or the
property owned or leased by it makes such qualification necessary. However, it
is hereby expressly stated that the deed of incorporation of Natac has been
filed with the Commercial Registry of Madrid but it is still pending for final
registration.

4.2          
The total share capital of Natac consists of 200 shares of capital
stock, with a par value of 15.03 Euros, of which 200 shares of capital stock are
issued and outstanding.

4.3          
Each of the Vendors is the legal, beneficial and recorded owner of the Natac
Shares set out next to his or her name in Section 2.1 hereto, with good and
marketable title thereto, free and clear of all mortgages, charges, liens,
security interests, adverse claims, pledges, encumbrances, and demands
whatsoever.

4.4          
  No person, firm or corporation has any agreement or option, including convertible
  securities, warrants or convertible obligations of any nature, or any right
  or privilege (whether by law, preemptive or contractual) capable of becoming
  an agreement or option for the purchase, subscription, allotment or issuance
  of any of the unissued shares in the capital of Natac. Except for the Natac
  Shares, nothing in this provision will restrict a shareholder of Natac from
  transferring his or her shares of Natac to a third party and Caleco agrees to
  waive any right of first refusal to acquire those shares of Natac.

4.5           
Natac will not, without the prior written consent of Caleco, issue any
additional shares or ownership interest in Natac or create any options, warrants
or rights for any person to subscribe for or acquire any unissued shares in the
capital of Natac from and after the date of this Agreement to the Closing Date.
Except for the Natac Shares, nothing in this provision will prevent a
shareholder of Natac from transferring his or her shares of Natac to a third
party

4.6           
This Agreement has been duly authorized, validly executed and delivered
by the Vendors, and acknowledged by Natac.

4.7           
The Vendors have full powers, capacity, and authority to enter into
this Agreement on the terms and conditions set forth herein, and this Agreement
and all other documents required to be executed and delivered by the Vendors
will when executed constitute, a validly and legally binding obligation of the
Vendors, enforceable in accordance with their terms, except (i) as may be
limited by applicable bankruptcy, insolvency, reorganisation, moratorium and
other laws of general application affecting the enforcement of creditors’ rights
generally, and (ii) as may be limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies .

4.8           
Each of the Vendors are not a “US Person” as defined under Regulation S
of the Securities Act and is not acquiring Caleco Shares for the benefit of any
US Person.

4.9           
The Vendors represent and warrant to Caleco that they are acquiring
Caleco Shares for investment purposes only, with no present intention of
dividing their interest with others or reselling or otherwise disposing of any
or all of the Caleco Shares.

4.10          
The Vendors were not in the United States at the time the offer to
acquire the Caleco Shares was received.

4.11          
The Vendors agree not to engage in hedging transactions with regard to
the Caleco Shares unless in compliance with the Securities Act.

4.12          
As at the date of this Agreement, Natac does not have outstanding any
bonds, debentures, mortgages, notes, loans or other indebtedness, and Natac is
not under any agreement to create or issue any bonds, debentures, mortgages,
notes or other indebtedness.

4.13          
As at the date of this Agreement, the total liabilities of Natac do not
exceed $20,000.

4.14          
There are no actions, suits or proceedings (whether or not purportedly
on behalf of Natac), pending or threatened against or affecting Natac or
affecting its business, at law or in equity, or before or by any federal, state,
municipal or other governmental department, commission, board, bureau, agency or
instrumentality, domestic or foreign and neither Natac nor the Vendors are aware
of any existing ground on which any such action, suit or proceeding might be
commenced with any reasonable likelihood of success.

4.15          
  Natac is not in material default or breach of any contracts, agreements, written
  or oral, indentures or other instruments to which it is a party and there are
  no facts, which, after notice or lapse of time or both, that would constitute
  such a default or breach, and all such contracts, agreements, indentures or
  other instruments are now in good standing and Natac is entitled to all benefits
  thereunder.

5.          
REPRESENTATIONS AND WARRANTIES OF CALECO

              
  Caleco represents and warrants to Natac and to the Vendors as follows and acknowledges
  that Natac and the Vendors are relying upon such representations and warranties
  in entering into this Agreement: 

5.1          
Caleco has been duly incorporated and organized and validly subsisting
under the laws of Nevada; it has the corporate power to own or lease its
properties and to carry on its business as now being conducted by it; and it is
duly qualified as a corporation to do business and is in good standing with
respect thereto in each jurisdiction in which the nature of its business or the
property owned or leased by it makes such qualification necessary.

5.2          
Caleco is a reporting issuer under the Exchange Act and is in good
standing with respect to all filings required to be made under such statutes
with the SEC.

5.3          
The authorized capital of Caleco consists of 975,000,000 shares of
common stock with a par value of $0.001 per share. There are 87,454,674 shares
of common stock currently issued and outstanding as fully paid and
non-assessable shares.

5.4          
No person, firm or corporation has any agreement or option, including
convertible securities, warrants or convertible obligations of any nature, or
any right or privilege (whether by law, preemptive or contractual) capable of
becoming an agreement or option for the purchase, subscription, allotment or
issuance of any of the unissued shares in the capital of Caleco.

5.5          
This Agreement has been duly authorized, validly executed and delivered by
Caleco.

5.6          
The Caleco Shares when issued and sold in accordance with the terms of this
Agreement, will be (1) duly and validly issued, fully paid and non-assessable,
(2) free and clear from all liens, pledges, security interests and other
encumbrances and restrictions on transfer other than restrictions on transfer
under applicable state and federal securities laws and (3) issued in accordance
with all applicable state and federal securities laws.

5.7          
  There are no actions, suits or proceedings (whether or not purportedly
  on behalf of Caleco), pending or threatened against or affecting Caleco or affecting
  its business, at law or in equity, or before or by any federal, state, municipal
  or other governmental department, commission, board, bureau, agency or instrumentality,
  domestic or foreign and Caleco is not aware of any existing ground on which
  any such action, suit or proceeding might be commenced with any reasonable likelihood
  of success.

5.8          
  Caleco hereby and in favour of the Vendors waives for any future pre-emptive
  right over Natac shares if, as a consequence of exercising such right Caleco
  would raise its participation in Natac over 18%.

6.           
CONDITIONS OF CLOSING

6.1          
All obligations of the parties under this Agreement are subject to the
fulfilment, at or prior to the Closing Date, of the following conditions:

	 	(a) 	 The respective representations and warranties contained
        in this Agreement or other document delivered to any of the parties pursuant
        hereto shall be substantially true and correct as of the date hereof and
        as of the Closing Date with the same force and effect as though such representations
        and warranties had been made on and as of such date, regardless of the
        date as of which the information in this Agreement is given;

	 	(b) 	 Caleco and Natac shall complete the closing of a research
        and licensing agreement pursuant to which Caleco will acquire an exclusive
        license in North and South America to certain probiotic strains from breast
        milk, and developed for: (i) prevention or treatment of human mastitis;
        (ii) use as infant formula; (iii) treatment of human gastrointestinal
        disease; (iv) human immune stimulant activity; (v) animal nutritional
        improvements; and (vi) prevention or treatment of pig mastitis,

	 	 	 
	 	(c) 	 Caleco and Natac shall complete the closing of an exclusive
        licensing agreement pursuant to which Caleco will acquire an exclusive
        license in North and South America to certain products, including, CRVO,
        AOF, AH-FLO, JHF, HGF and NB- VAL 40;

	 	 	 
	 	(d) 	 Caleco and Natac shall complete the closing of a lab
        facilities and services agreement pursuant to which Natac shall provide
        certain services and laboratory access to Caleco;

	 	 	 
	 	(e) 	 Natac and the Vendors will complete all necessary approvals
        and all necessary steps and corporate proceedings have been obtained or
        taken to permit the Natac Shares to be duly and validly transferred to
        and registered in the name of Caleco; and

	 	 	 
	 	(f) 	 Caleco will complete all necessary approvals and all
        necessary steps and corporate proceedings have been obtained or taken
        to permit the Caleco Shares to be duly and validly issued to and registered
        in the name of the Vendors.

7.          
CLOSING ARRANGEMENTS

7.1          
The closing of this Agreement shall occur on a date, time and place as
mutually agreed to by the parties, but in any event no later than March 19, 2010
(the “Closing Date”).

7.2          
On the Closing Date, upon fulfilment of the conditions set out in
paragraph 6.1, then:

	 	(a) 	
      the Vendors and Natac shall deliver to Caleco:

	 	 	 	 
	 		(i) 	
      a certificate issued by Natac Administrator evidencing
      that the transfer of the Natac Shares has been duly recorded in the
      company book of Shareholders (“Libro Registro de Socios”) in favour of
      Caleco free and clear of all liens, charges and encumbrances of any kind
      whatsoever; and

	 	 	 	 
	 		(ii) 	
      evidence satisfactory to Caleco and its legal counsel of
      the appointment of Caleco’s nominee to the Board of Directors of
    Natac.

	 	 	 	 
	 	(b) 	
      Caleco shall issue, execute and deliver to Natac and the
      Vendors:

	 	 	 	 
	 		(i) 	
      share certificates representing the Caleco Shares in the
      name of each Vendor; and

	 	 	 	 
	 		(ii) 	
      evidence satisfactory to Natac and its legal counsel of
      the appointment of Natac’s nominee to the Board of Directors of
    Caleco.

8.            
GENERAL PROVISIONS

8.1          
Time shall be of the essence of this Agreement.

8.2          
This Agreement contains the whole agreement between the parties hereto
in respect of the purchase and sale of the Natac Shares and there are no
warranties, representations, terms, conditions or collateral agreements
expressed, implied or statutory, other than as expressly set forth in this
Agreement.

8.3          
This Agreement shall enure to the benefit of and be binding upon the parties
hereto and their respective successors and permitted assigns. Caleco may not
assign this Agreement without the consent of Natac which consent may be withheld
for any reason whatsoever.

8.4          
Any notice to be given under this Agreement shall be duly and properly
given if made in writing and delivered or telecopied to the addressee at the
address as set out on page one of this Agreement. Any notice given as aforesaid
shall be deemed to have been given or made on, if delivered, the date on which
it was delivered or, if telecopied, on the next business day after it was
telecopied. Any party hereto may change its address for notice from time to time
by providing notice of such change to the other parties hereto in accordance
with the foregoing.

8.5          
This Agreement shall be construed and enforced in accordance with, and
the rights of the parties shall be governed by: (i) the laws of the State of
Nevada to all issues related to Caleco and to the issuance of Caleco Shares;
and; (ii) the laws of the Kingdom of Spain to all issues related to Natac and to
the transfer of Natac Shares.

8.6          
Any dispute, controversy or claim arising out of or in connection with
this Agreement, or the breach, termination or invalidity thereof, the parties
renounce expressly to any other applicable jurisdiction, and submit to
arbitration of law before the International Chamber of Commerce of Paris. Any
matter presented for arbitration will be settled by arbitration proceedings
conducted by one arbitrator. The decision of the arbitrator as to any matter in
dispute under this Agreement will be binding and conclusive upon the parties.
The decision of the arbitrators will be rendered in writing and will include the
basis for the decision. Execution of the judgment upon any award rendered by the
arbitrator may be entered in any court having jurisdiction

- THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK
-

8.7          
This Agreement may be executed in one or more counter-parts, each of
which so executed shall constitute an original and all of which together shall
constitute one and the same agreement.

IN WITNESS WHEREOF the parties hereto have executed this
Agreement as of the day and year first above written.

NATAC BIOTECH S.L.

  

  /s/ Antonio Delgado Romero

  By Its Authorized
Signatory

SIGNED, SEALED AND DELIVERED
BY ANTONIO DELGADO
ROMERO
in the presence of: 

	/s/ Jose Carlos Quintela Fernandez	/s/ Antonio Delgado Romero
	Signature of Witness 	ANTONIO DELGADO ROMERO

Jose Carlos Quintela Fernandez

  Name

  _______________________________

  

  SIGNED, SEALED AND DELIVERED

  BY JOSE CARLOS QUINTELA FERNANDEZ

  in the presence of: 

	/s/ Antonio Delgado Romero	/s/ Jose Carlos Quintela Fernandez
	Signature of Witness 	JOSE CARLOS QUINTELA FERNANDEZ
  

Antonio Delgado Romero

  Name

  _______________________________

  CALECO PHARMA CORP.

  

  

  /s/ John Boschert

  By Its Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00168-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00168-of-00352.parquet"}]]